Lifting limits: liposomal delivery of chemotherapy for secondary AML with CPX-351
Elderly patients with secondary acute myeloid leukemia (AML) typically had poor outcomes following standard chemotherapy treatment. However, this changed in August 2017 with the approval of CPX-351 fo...
Author: VJHemOnc
Added: 03/08/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 8, 2018 Category: Cancer & Oncology Source Type: podcasts
Liposomal chemotherapy CPX-351: safety profile
CPX-351, a combination of cytarabine (ara-C) and daunorubicin within a liposomal delivery system, was approved in August 2017 for two types of secondary acute myeloid leukemia (AML). Speaking from the...
Author: VJHemOnc
Added: 03/08/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 8, 2018 Category: Cancer & Oncology Source Type: podcasts
What are the next steps for liposomal chemotherapy delivery and CPX-351?
The liposomal delivery of chemotherapy is a promising therapeutic area, which was highlighted by the approval of CPX-351 for two types of typically hard-to-treat secondary acute myeloid leukemia (AML)...
Author: VJHemOnc
Added: 03/08/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 8, 2018 Category: Cancer & Oncology Source Type: podcasts
Making an IMPACT in ALL therapy: how can cure rates be improved?
Hear about exciting advancements in acute lymphocytic leukemia (ALL) with Prof. David Marks, MBBS, PhD, FRACP, FRCPath, of University Hospitals Bristol NHS Foundation Trust, Bristol, UK, who discusses...
Author: VJHemOnc
Added: 03/08/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 8, 2018 Category: Cancer & Oncology Source Type: podcasts
Nelarabine as first-line treatment for T-cell ALL: facing the problem up-front
Nelarabine has shown to be effective in treating relapsed/refractory T-cell acute lymphocytic leukemia (T-ALL) in children and adults; however, there are known concerns about its upfront use for T-ALL...
Author: VJHemOnc
Added: 03/08/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 8, 2018 Category: Cancer & Oncology Source Type: podcasts
Rituximab vs. standard chemotherapy: which treatment benefits B-cell ALL patients more?
Can patients with B-cell acute lymphocytic leukemia (ALL) benefit more from using rituximab as part of their treatment compared to using standard chemotherapy alone? This is one question that Prof. Da...
Author: VJHemOnc
Added: 03/08/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 8, 2018 Category: Cancer & Oncology Source Type: podcasts
Update on checkpoint inhibitor therapy for AML: salvage, frontline & amp; azacitidine combination
The use of immune checkpoint inhibitor therapy for acute myeloid leukemia (AML) has progressed drastically over the past several years. Speaking from the 1st International Workshop on Acute Leukemias ...
Author: VJHemOnc
Added: 03/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 6, 2018 Category: Cancer & Oncology Source Type: podcasts
Targeting sonic hedgehog signaling in AML
Aberrations in sonic hedgehog (shh) signaling are known to be associated with certain types of cancer, including acute myeloid leukemia (AML). In this interview, Jorge Cortes, MD, of the MD Anderson C...
Author: VJHemOnc
Added: 03/05/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 5, 2018 Category: Cancer & Oncology Source Type: podcasts
Smoothening the spines: hedgehog signaling inhibitor glasdegib combinations for AML
Therapeutically targeting the sonic hedgehog (shh) signaling pathway for the treatment of acute myeloid leukemia (AML) is an exciting area, with Smoothened (SMO) inhibitors already used successfully i...
Author: VJHemOnc
Added: 03/05/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 5, 2018 Category: Cancer & Oncology Source Type: podcasts
iwAL 2018 day 2 discussion: novel approaches and targeted therapies in AML
A plethora of novel treatments for acute myeloid leukemia (AML) are emerging, providing an increasing choice of therapies and bringing up important questions for further study. These intriguing topics...
Author: VJHemOnc
Added: 03/02/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 2, 2018 Category: Cancer & Oncology Source Type: podcasts
Acute leukemias discussion: what does genomics and epigenomics tell us about patient management?
A stimulating session on the implications of genomic data for the management of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) patients was hosted at the 1st International Worksho...
Author: VJHemOnc
Added: 03/02/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 2, 2018 Category: Cancer & Oncology Source Type: podcasts
Genomics and acute leukemia management: artificial intelligence, deep learning & amp; pre-leukemic clones
An interesting session on the impact of genomic data on the management of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) was held at the 1st International Workshop on Acute Leukem...
Author: VJHemOnc
Added: 03/02/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 2, 2018 Category: Cancer & Oncology Source Type: podcasts
Recent subtypes of ALL: Ph-like ALL and ETP ALL
Recent insights from the genomic analysis of acute lymphoblastic leukemia (ALL) were presented at the 1st International Workshop on Acute Leukemias (iwAL), held in St. Pete Beach, FL. Filmed at the me...
Author: VJHemOnc
Added: 03/02/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 2, 2018 Category: Cancer & Oncology Source Type: podcasts
The evolving genomic landscape of ALL: molecular genetics, profiling and classification
The genomic analysis of acute lymphoblastic leukemia (ALL) is providing novel insights into the disease, which will inform and direct treatment decisions and research. The 1st International Workshop o...
Author: VJHemOnc
Added: 03/02/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 2, 2018 Category: Cancer & Oncology Source Type: podcasts
Challenging the norms for elderly AML treatment: clinical trials & amp; intensive therapy
Acute myeloid leukemia (AML) is typically a disease affecting older people, and there are increasing numbers of elderly AML patients due to ageing populations; however, this group is often discounted ...
Author: VJHemOnc
Added: 03/02/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 2, 2018 Category: Cancer & Oncology Source Type: podcasts
